Hematology– In the Department of Medicine

Recent Publications: Peter Greenberg MD

  1. Han JH, Gileadi C, Rajapaksa R, Kosek J, Greenberg PL:  Modulation of myeloid leukemic cell apoptosis by GM-CSF.  Exp Hematol, 23:265-272,1995
  2. Schriber JR, Dejbakhsh-Jones S, Kusnierz-Glaz C, Ginzton N, Stills B, Negrin R, Greenberg P, Strober S:  Enrichment of bone marrow and blood progenitors (CD34) cells by density gradients with sufficient yields for transplantation. Exp. Hematol 23:1024-1029, 1995
  3. Rajapaksa R, Ginzton N, Rott L, Greenberg PL:  Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275-4287, 1996.
  4. Greenberg PL: Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes.  Seminars Hematol 33:163-175,1996.
  5. Greenberg P, Cox C, Le Beau MM, et al: International scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood 89: 2079-2088, 1997.
  6. Davis RE, Greenberg PL: Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Impact on disease progression. Leuk Res 22: 767-777. 1998.
  7. Greenberg PL: Apoptosis and its role in MDS: Implications for disease natural history and treatment. Leukemia Research 22: 1123-1136, 1998.
  8. Greenberg PL,  Sanz GF, Sanz MA: Prognostic scoring systems for risk assessment in myelodysplastic syndromes. FORUM Trends in Exp Clin Med 9(1): 17-31, 1999.
  9. Greenberg PL:  The Myelodysplastic Syndromes. In: Hematology: Basic Principles and Practice. 3rd Ed., Hoffman R, Benz E, Shattil S, Cohen H, Eds. Churchill Livingstone, NY, 2000, 1106-1129.
  10. Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, Appelbaum F, Greenberg P: Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndromes.  Leukemia 16:162-164, 2002.
  11. Gotlib J, Greenberg P, Myelodysplastic Syndromes, In: Leukemia, 7th Edition, Eds E Henderson, TA Lister,  M Greaves, Saunders; Elsevier Science, Philadelphia, PA, 2002, pp 545-582.
  12. Greenberg P,  Young N, Gattermann N. 'Controversies and Therapeutic Options in MDS: Biologically Targeted Approaches', In: Hematology 2002, ASH Education Program Book, Washington, DC, 2002, pp 136-161.
  13. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Higgins RR, Bennet JM, Greenberg PL, et al: Comparison of interphase FISH and metaphase cytogenetics to study  myelodysplasia: an Eastern Cooperative Oncology Group (ECOG) study. Leukemia Research 27:1085-1090, 2003.
  14. Gotlib J, Greenberg P: Hematopoietic Growth Factor Therapy for Myelodysplastic Syndrome and Aplastic Anemia, In : Hematopoietic Growth Factors In Oncology:  Basic Science and Clinical Therapeutics, G Morstyn, MA Foote, G Lieschke, Eds, Humana Press, Totowa, NJ, 2003,  pp 333-355.
  15. Gotlib J, Greenberg P: Novel biospecific agents for the treatment of myelodysplastic syndromes. J Nat Compr Cancer Network 1: 473-480, 2003.
  16. Greenberg P, Lee S, Advani R, et al: Mitoxantrone, Etoposide and Cytarabine with or without Valspodar in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995), J Clin Oncol  22:1078-1086,  2004.
  17. Cutler C, Lee SJ, Greenberg P, et al.  A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes:  Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome. Blood 104: 579-585, 2004.
  18. Fukumoto J, Greenberg PL, Management of patients with higher risk myelodysplastic syndromes.  Critical Reviews in Oncology/Hematology 56: 179-192, 2005.
  19. Greenberg P, New therapies and the role of hematopoietic stem cell transplantation in myelodysplastic syndromes. Haema 8 (Suppl 1): S35-43, 2005.
  20. Sridhar K, Brown PO, Tibshirani R, Jamieson C, Weissman I, Ross DT, Greenberg PL. Differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells. Blood 106 (#11): 954a, 2005.
  21. Greenberg PL,  Editor, Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge University Press, Cambridge, England, 2006, Including chapters:, Greenberg PL: 'Clinical and Prognostic Characterization of Myelodysplastic  Syndrome', 'Pathogenetic Mechanisms Underlying Myelodysplastic Syndrome', 'Supportive Care in Myelodysplastic Syndromes: Hemopoietic Cytokine and Iron Chelation Therapy'.
  22. Greenberg PL, Bennett J, Bloomfield C, et al:  NCCN Practice Guidelines for Myelodysplastic Syndromes, Version 1. 2006, J Nat Comp Canc Network 4:58-77, 2006.
  23. Greenberg PL, Myelodysplastic Syndromes: Iron overload consequences and current chelating  therapies,  J National Comp Canc Network 4: 91-96, 2006
  24. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425, 2006.
  25. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek L, Morris L, Park Y, Adjei A, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia. Blood 109: 1387-1394, 2006.
  26. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B,  Greenberg P, et al. Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. New Engl J Med 355:1456-1465, 2006.
  27. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and  standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference. Leukemia Research 31:727-736, 2007.
  28. Kao JM, Greenberg PL: Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods. Clinical Leukemia 1: 172-182, 2007.
  29. Park S, Grabar S, Kelaidi C, .Bourgeois K, Greenberg P, Fenaux P, Dreyfus F. For the Groupe Francophone des myélodysplasies (GFM). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111: 574-582, 2008.
  30. Raza A, Reeves JE, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin P, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q. Blood 111:86-93, 2008.
  31. Porter J, Galanello R, Saglio S, Neufeld E, Vichinsky E, Cappellini M, Olivieri N, Piga A, Cunningham M, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni G, Stadler M, Cario H, Debusscher HL, Della Porta M, Cazzola M, Greenberg P, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study. Eur J Haematology 80:168-76, 2008.
  32. Raponi M, Lancet J, Fan H, Dossey L, Lee G, Gojo I, Feldman E, Gotlib J, Morris L, Greenberg P, Wright J, Harousseau J, Löwenberg B, Stone R, De Porre P, Wang Y, Karp J. A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111: 2589-96, 2008.
  33. Sloand EM, Wu C, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26: 2505-11, 2008.
  34. Kao JM, McMillan A, Greenberg PL, International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed:  Impact of Cytopenias on Clinical Outcomes in Myelodysplastic Syndrome, Am J Hematology, 2008, in press.
  35. Greenberg PL, Cosler LE, Ferro SA, Lyman GH,  The Costs of Drugs Used to Treat Myelodyplastic Syndromes Following National Comprehensive Cancer Network Guidelines, J Natl Comp Cancer Network, Oct 2008, in press.
  36. Park S, Grabar S, Kelaidi C, …,  Greenberg P, et al. For the Groupe Francophone des myélodysplasies (GFM). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111: 574-582, 2008.
  37. Greenberg PL, Battiwalla M, Bennett JM, et al: NCCN Practice Guidelines for Myelodysplastic Syndromes, Version 1. 2009, J Nat Compr Cancer Network, October 2008, in press.
     
Back to: Peter Greenberg Laboratory

Stanford Medicine Resources:

Footer Links: